Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

Apr 28, 2026

FDA Grants Fast Track to Coramitug for ATTR-CM, Supporting Amyloid-Clearing Phase 3 Trial

Read more

Apr 28, 2026

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

Read more

Apr 28, 2026

Quantitative imaging in cardiac transthyretin amyloidosis: rationale and design of the i-CARE study

Read more

Apr 27, 2026

FDA grants fast track status to Novo Nordisk’s ATTR-CM drug

Read more

Apr 27, 2026

Study Finds Less Advanced Disease in Recent ATTR-CM Trials

Read more

Apr 27, 2026

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Read more

Apr 27, 2026

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Read more

Apr 27, 2026

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Read more

Apr 21, 2026

Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review

Read more

Apr 20, 2026

Carpal tunnel in both wrists may be ‘red flag’ for ATTR: Study

Read more

Subscribe to